DB:E031

Stock Analysis Report

Executive Summary

ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has ESSA Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: E031's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.7%

E031

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

16.6%

E031

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: E031 exceeded the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: E031 exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

E031IndustryMarket
7 Day10.7%11.7%9.9%
30 Day-19.6%-5.9%-16.6%
90 Day-28.2%-22.6%-24.8%
1 Year16.6%16.6%-7.9%-8.1%-15.0%-17.5%
3 Yearn/a16.6%15.4%-17.4%-24.5%
5 Yearn/a-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is ESSA Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ESSA Pharma undervalued compared to its fair value and its price relative to the market?

1.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate E031's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate E031's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: E031 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: E031 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate E031's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: E031 is good value based on its PB Ratio (1.7x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is ESSA Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-15.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: E031 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: E031 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: E031 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if E031's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if E031's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if E031's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ESSA Pharma performed over the past 5 years?

-7.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: E031 is currently unprofitable.

Growing Profit Margin: E031 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: E031 is unprofitable, and losses have increased over the past 5 years at a rate of -7.7% per year.

Accelerating Growth: Unable to compare E031's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: E031 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: E031 has a negative Return on Equity (-26.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is ESSA Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: E031's short term assets ($46.8M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: E031's short term assets ($46.8M) exceed its long term liabilities ($105.8K).


Debt to Equity History and Analysis

Debt Level: E031 is debt free.

Reducing Debt: E031 had no debt 5 years ago.


Balance Sheet

Inventory Level: E031 has a low level of unsold assets or inventory.

Debt Coverage by Assets: E031's debt is not covered by short term assets (assets are -1.6845742148353E+18x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: E031 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: E031 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -8.9% each year


Next Steps

Dividend

What is ESSA Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate E031's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate E031's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if E031's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if E031's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of E031's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

David Parkinson (69yo)

4.17s

Tenure

US$995,534

Compensation

Dr. David Ross Parkinson, M.D., has been an Independent Director of Tocagen Inc. since April 2015. Dr. Parkinson has been a Director of Realm Therapeutics plc. since July 31, 2019. He has been the Chief Ex ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD995.53K) is above average for companies of similar size in the German market ($USD431.45K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
David Parkinson
President4.17yrsUS$995.53k0.060% $42.9k
David Wood
Chief Financial Officer6.67yrsUS$406.67k0.30% $215.8k
Peter Virsik
Executive VP & COO3.58yrsUS$792.29k0.50% $355.7k
Marianne Sadar
Scientific Advisor0.75yrUS$229.20k0.93% $661.0k
Alessandra Cesano
Chief Medical Officer0.67yrno datano data
Edward Scolnick
Scientific Advisorno datano datano data
Chandtip Chandhasin
Executiveno datano datano data
Erica Osbourne
Executiveno datano datano data
Erin Rudsinski
Executiveno datano datano data
Leah Dimascio
Executiveno datano datano data

3.6yrs

Average Tenure

60yo

Average Age

Experienced Management: E031's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Parkinson
President4.17yrsUS$995.53k0.060% $42.9k
Sanford Zweifach
Independent Director0.67yrUS$5.17kno data
Richard Glickman
Independent Chairman of the Board9.42yrsUS$87.89k0.19% $132.9k
Gary Sollis
Independent Director7.92yrsUS$69.74kno data
John Martin
Director0.67yrUS$5.17k0.069% $49.0k
Franklin Berger
Independent Director5yrsUS$61.49k2.68% $1.9m
Scott Requadt
Independent Director4.17yrsUS$59.47kno data
Marella Thorell
Director0.67yrUS$5.17k0.014% $9.9k
Ari Brettman
Director0.42yrno datano data

4.2yrs

Average Tenure

62yo

Average Age

Experienced Board: E031's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: E031 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 108.5%.


Top Shareholders

Company Information

ESSA Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ESSA Pharma Inc.
  • Ticker: E031
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$111.410m
  • Listing Market Cap: CA$71.396m
  • Shares outstanding: 20.82m
  • Website: https://www.essapharma.com

Number of Employees


Location

  • ESSA Pharma Inc.
  • 999 West Broadway
  • Suite 720
  • Vancouver
  • British Columbia
  • V5Z 1K5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPITSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2015
EPIXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2015
E031DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2015

Biography

ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 23:37
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.